Osprey have been in a depressed SP position for a number of...

Osprey have been in a depressed SP position for a number of years wholly on the fact that administration costs exceeded to to income derived from sales, distribution, marketing and training within the USA alone, despite the known benefit of the technology device to reduce kidney damage from over exposure to contrast dye.

The GE deal has been in the pipeline for sometime and when executed will see a rapid return to balanced costs and eventually profit IMO, I suspect the GE deal has been waiting on a number of developments before any contract terms being signed.....The first being the Dyeminish program to prove the the device works and efficiencies gained, secondly the latest capital raising to ensure that Osprey is well funded moving forward to provide not only the technology but the training and support required for GE Health to push this to the geographic areas under their agreement.

All the above have been ticked and positive light in the coming years, final tick will be the signatures of GE and Oprey executives

Keep well cheers Paul